Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | TPMT | P51580 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678875 | 0.89 | MAPT (0.64) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL5169870 | 0.89 | MAPT (0.64) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL901309 | 0.87 | CA12 (0.71) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL29446743 | 0.87 | CA12 (0.71) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL5168276 | 0.86 | CA12 (0.65) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL644612 | 0.86 | MAPT (0.60) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL30456978 | 0.86 | CA12 (0.65) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL1561739 | 0.86 | MAPT (0.60) | MAPTCA1CA2CA12CA7 | |
| Hydrochloric Acid SCHEMBL11840020 | 0.85 | CA12 (0.69) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL28007167 | 0.85 | CA12 (0.69) | MAPTCA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289793-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4519251-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | Esperion Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119137107-A | Macrocyclic inhibitors of ATP citrate lyase | 艾斯柏伦治疗公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118580241-A | Tetrahydropyrrolo [3,4-c ] pyrazole compound, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023215220-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| EP-1270558-B1 | \"Compound for the treatment of atherosclerotic-thrombotic pathological conditions\ | CASAGRANDE CESARE (IT) | 2007-04-25 | — | — | EP | disclosed |
| US-6525078-B1 | Compound for the treatment of atherosclerotic-thrombotic pathological conditions | CASAGRANDE CESARE (IT) | 2003-02-25 | — | — | US | disclosed |
| EP-1270558-A1 | \"Compound for the treatment of atherosclerotic-thrombotic pathological conditions\ | Casagrande, Cesare (IT) | 2003-01-02 | — | — | EP | disclosed |
| WO-1997003967-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL USE | RHONE-POULENC RORER LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | MAPT 2367/4885CA1 4235/4885CA2 1289/4885 |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | MAPT 727/4885CA1 1262/4885CA2 170/4885 |
| US-20250289793-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ACLY, CS, ATP5ME | MAPT 3473/4885CA1 1569/4885CA2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.